Who is sponsoring NCT00028132?

NCT00028132 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What condition does NCT00028132 study?

NCT00028132 studies HIV Infections.

What is the status of NCT00028132?

NCT00028132 is currently COMPLETED.

Last reviewed 2021-10-28 · How we verify

Phase I Safety and Acceptability Study of the Vaginal Microbicide Agent PMPA Gel

NCT00028132 Phase 1 COMPLETED

The purpose of this study is to evaluate the PMPA gel, which kills microbes, in HIV-infected and HIV-uninfected women. The majority of new HIV infections occur through heterosexual contact. A product that stops or slows the replication of HIV during sexual contact is needed. At present, there are no products that are completely effective. PMPA gel, also known as tenofovir, is an anti-microbe agent that may fight against sexual transmission of HIV and other sexually transmitted diseases (STDs). It is applied to the vagina and gives women the ability to control their disease-prevention activity.

Details

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Phase	Phase 1
Status	COMPLETED
Enrolment	120
Completion	2005-12

Conditions

HIV Infections

Interventions

Tenofovir

Countries

United States